Pan‑cancer analysis identified ARHGAP23 as a potential biomarker for pancreatic adenocarcinoma

Xiaolong Liu; Xin Li; Ling Wang; Kaihua Yu; Dean Wu; Pengxian Tao; Yulan Li

doi:10.3892/mco.2023.2696

Pan‑cancer analysis identified ARHGAP23 as a potential biomarker for pancreatic adenocarcinoma

Mol Clin Oncol. 2023 Nov 3;19(6):100. doi: 10.3892/mco.2023.2696. eCollection 2023 Dec.

Authors

Xiaolong Liu¹, Xin Li², Ling Wang³, Kaihua Yu¹, Dean Wu¹, Pengxian Tao⁴, Yulan Li¹

Affiliations

¹ The First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
² The General Surgery Department, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China.
³ Department of Pathology, Lanzhou, Gansu 730000, P.R. China.
⁴ Cadre Ward of General Surgery Department, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China.

Abstract

Rho GTPASE-activating protein 23 (ARHGAP23) is known to activate RHO-GTPase and has an important role in the infiltration and metastasis of tumors. Although previous studies suggested its involvement in certain human cancers, its role in pan-cancer remains unclear. In the present study, the expression, prognosis and potential functions of ARHGAP23 in pan-cancer were evaluated through various public databases such as Human Protein Atlas, Tumor IMmune Estimation Resource, Gene Set Co-Expression Analysis, Gene Expression Profiling Interactive Analysis, cBio Cancer Genomics Portal, Tumor-Immune System Interactions Database (TISIDB) and others. Through these data combined with a variety of biological information analysis methods, the potential role of ARHGAP23 as a carcinogenic gene was explored in the present study. The present analysis revealed that ARHGAP23 expressed abnormalities in >10 tumors, which was associated with differences in prognosis. Furthermore, the findings of the present study indicated that ARHGAP23 is associated with DNA methylation and multiple immune cell infiltrations in these tumors. ARHGAP23 expression was related to clinical prognosis, DNA methylation and immune infiltration. These findings support the potential of ARHGAP23 as a prognostic biomarker and a molecular target for cancer treatment.

Keywords: Rho GTPASE-activating protein 23; biomarker; pan-cancer; pancreatic adenocarcinoma; prognosis.

Grants and funding

Funding: The present study was supported by the 2022 Natural Science Foundation of Gansu Province (grant nos. 2022-0405-JCC-0319, 21JR7RA412 and 20JR5RA145), Key Project of Science and Technology Innovation Platform Fund of Gansu Provincial People's Hospital (grant no. 21gssya-4), Postdoctoral Fund of Gansu Provincial People's Hospital (grant nos. ZX-62000001-2022-010 and ZX-62000001-2022-055) and Key Talent Project of Gansu Province (grant no. 2022RCXM025).